Ubs Global Asset Management Americas Inc increased Phibro Animal Health Corp A (PAHC) stake by 12.38% reported in 2019Q1 SEC filing. Ubs Global Asset Management Americas Inc acquired 1,134 shares as Phibro Animal Health Corp A (PAHC)’s stock declined 1.18%. The Ubs Global Asset Management Americas Inc holds 10,292 shares with $339.64M value, up from 9,158 last quarter. Phibro Animal Health Corp A now has $1.23B valuation. The stock increased 0.26% or $0.08 during the last trading session, reaching $30.44. About 44,655 shares traded. Phibro Animal Health Corporation (NASDAQ:PAHC) has declined 34.87% since July 12, 2018 and is downtrending. It has underperformed by 39.30% the S&P500. Some Historical PAHC News: 10/05/2018 – Phibro Events and Innovations Expand Dairy Industry Collaboration, Knowledge of DCAD Nutrition; 07/05/2018 – Phibro Animal Health Corporation Declares Quarterly Dividend; 19/04/2018 – DJ Phibro Animal Health Corporation Cl, Inst Holders, 1Q 2018 (PAHC); 07/05/2018 – PHIBRO ANIMAL 3Q ADJ EPS 46C, EST. 42C; 02/04/2018 – Thornburg Value Adds Starbucks, Exits Phibro Animal; 07/05/2018 – Phibro Animal Health Corporation Reports Third Quarter; 19/04/2018 – Phibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2018 Health Care Conference; 07/05/2018 – Phibro Animal Health 3Q EPS 49c; 07/05/2018 – PHIBRO ANIMAL HEALTH CORP QTRLY DILUTED EPS OF $0.49; 20/04/2018 – Phibro Animal Presenting at Bank of America Conference May 16
Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.55 EPS on August, 8.They anticipate $0.43 EPS change or 358.33% from last quarter’s $-0.12 EPS. After having $-0.43 EPS previously, InflaRx N.V.’s analysts see 27.91% EPS growth. The stock decreased 1.83% or $0.06 during the last trading session, reaching $3.22. About 468,230 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 12, 2018 and is uptrending. It has outperformed by 16.11% the S&P500. Some Historical IFRX News: 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018
Ubs Global Asset Management Americas Inc decreased Harley Davidson Inc (NYSE:HOG) stake by 756 shares to 570,955 valued at $20.36B in 2019Q1. It also reduced Skyworks Solutions Inc (NASDAQ:SWKS) stake by 68,817 shares and now owns 1.06M shares. Ansys Inc (NASDAQ:ANSS) was reduced too.
Since January 15, 2019, it had 0 buys, and 4 insider sales for $1.47 million activity. Bendheim Daniel M sold $306,478 worth of stock or 9,780 shares. Another trade for 21,560 shares valued at $685,824 was sold by Warras Dean J.
More notable recent Phibro Animal Health Corporation (NASDAQ:PAHC) news were published by: Finance.Yahoo.com which released: “Did Phibro Animal Health’s (NASDAQ:PAHC) Share Price Deserve to Gain 45%? – Yahoo Finance” on June 12, 2019, also Finance.Yahoo.com with their article: “Does Phibro Animal Health Corporation’s (NASDAQ:PAHC) CEO Salary Compare Well With Others? – Yahoo Finance” published on May 14, 2019, Nasdaq.com published: “Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for June 04, 2019 – Nasdaq” on June 03, 2019. More interesting news about Phibro Animal Health Corporation (NASDAQ:PAHC) were released by: Nasdaq.com and their article: “Phibro (PAHC) Up 3.1% Since Last Earnings Report: Can It Continue? – Nasdaq” published on June 05, 2019 as well as Globenewswire.com‘s news article titled: “Phibro Animal Health Corporation Reports Third Quarter Results – GlobeNewswire” with publication date: May 06, 2019.
Investors sentiment decreased to 1.21 in 2019 Q1. Its down 0.18, from 1.39 in 2018Q4. It turned negative, as 21 investors sold PAHC shares while 49 reduced holdings. 19 funds opened positions while 66 raised stakes. 18.93 million shares or 1.67% less from 19.25 million shares in 2018Q4 were reported. Barclays Public Ltd Com holds 0% or 16,328 shares in its portfolio. 66,162 are held by South Dakota Investment Council. Millennium Mngmt Ltd Liability Corporation invested in 0.01% or 189,977 shares. First Manhattan Communication holds 0% or 3,000 shares. Zebra Cap Ltd has 7,059 shares. Menta Limited Liability Co has 42,292 shares. Adams Diversified Equity Fund Inc reported 0.01% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC). Fiduciary Management Incorporated Wi reported 0.05% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC). Cambiar Investors Limited Liability Corp holds 102,908 shares. S Muoio Co Ltd Liability Com holds 0.3% or 10,036 shares in its portfolio. Laurion Capital Ltd Partnership has 0% invested in Phibro Animal Health Corporation (NASDAQ:PAHC) for 10,317 shares. Tudor Corporation Et Al has 0.02% invested in Phibro Animal Health Corporation (NASDAQ:PAHC) for 16,007 shares. Dimensional Fund Advisors Limited Partnership, Texas-based fund reported 542,922 shares. Arizona State Retirement System holds 31,291 shares. Mason Street Advsr Ltd Com stated it has 6,514 shares or 0% of all its holdings.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $83.61 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Finance.Yahoo.com which released: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” on June 29, 2019, also Benzinga.com with their article: “28 Stocks Moving In Friday’s Pre-Market Session – Benzinga” published on July 12, 2019, Nasdaq.com published: “InflaRx Enters Oversold Territory – Nasdaq” on June 13, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Full Year 2018 Financial & Operating Results – GlobeNewswire” published on March 28, 2019 as well as Benzinga.com‘s news article titled: “InflaRx Shares Slammed As Skin Inflammation Drug Flunks Midstage Trial; ChemoCentryx Moves In Sympathy – Benzinga” with publication date: June 05, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.